Items tagged with Treatment

Intravenous rifampicin reintroduced in South Africa (post with simple image)

Equity Pharmaceuticals is the new supplier of the drug.

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid (post with simple image)

As countries improve and scale up their diagnostic services, increasing number of patients with multidrug-resistant TB and extensively drug-resistant TB are identified. Bedaquiline and delamanid offer a real opportunity to improve the outcomes of these patients. After so many decades without new TB drugs the development of these two new medicines is an historic opportunity to gain ground in the fight against TB.

Do we have the will to stop TB? (post with simple image)

Doctors swear to do no harm, but I knew I was about to inflict great suffering on my patient Gary, who had been diagnosed with extensively drug-resistant tuberculosis, or XDR TB. Many people wrongly assume that tuberculosis has been eradicated. In fact, according to the World Health Organization, tuberculosis killed more people in 2015 than HIV/AIDS.

(post with simple image)

TB Alliance and partners announce world’s first availability of appropriate, child-friendly TB medicines in correct doses (post with simple image)

Medication simplifies and improves treatment for 1 million children with TB; Medicines come in dispersible fixed-dose combinations at the correct dosages, tablets no longer need to be cut or crushed; These products can improve adherence and child survival from TB.

New cohort study shows promise of dramatically shorter treatment option for multidrug-resistant TB (post with simple image)

Initial results show 80% success rate using 9-month treatment option for MDR-TB, compared with 24-month treatment standard.

Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis (post with simple image)

Introducing bedaquiline and delamanid in TB programs worldwide has not kept pace with the need for these drugs. Coordinated global action might help assist making these medications accessible for persons who need them most.

Stop TB Partnership's Global Drug Facility jumpstarts access to new drugs for MDR-TB with innovative public-private partnerships (post with simple image)

The initiative will allow countries to access delamanid through the Stop TB Partnership’s Global Drug Facility at a price of US$ 1700 for each full-course treatment of six months’ duration.

Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments (post with simple image)

Médecins Sans Frontières released the 4th edition of its report DR-TB Drugs Under the Microscope. The report analyzes the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis.

Advocates call for WHO to update Delamanid Guidance to include children (post with simple image)

On World TB Day, and in light of new evidence of safety in children, advocates called on the World Health Organization to update its 2014 guidance on delamanid to include children.